Industry
These findings underscore MaaT013's potential as a third-line treatment option, where traditional treatments often fall short.
Researchers at the San Gallicano Dermatological Institute in Rome, Italy, conducted an open-label exploratory trial to assess the therapeutic potential of EUTOPLAC, a topical probiotic containing Lactobacillus crispatus P 17631…
Launching a new frontier in IBS management: the 'TrIuMPH' trial sets the stage with EBX-102-02, a pioneer in microbiome-based therapy.
The two companies will work on identifying, analyzing, and understanding respiratory tract microbiome systems.
Industry
Sponsored by
This partnership emerges as a strategic move to capitalize on the expanding global microbiome market.
Industry
Sponsored by
Harnessing the benefits of L. plantarum PBS067, L. rhamnosus LRH020, and B. lactis BL050 for post-menopausal symptom relief.
MaaT Pharma indicates completion of patient recruitment for the Phase 2a RCT Evaluating MaaT013 in combination with immune checkpoint inhibitors in metastatic melanoma.
This strategic acquisition is set to reshape the landscape of microbiome research, extending its applications far beyond human health.
The study seeks to identify specific microbial and metabolic markers in the small intestinal fluid and blood of PD patients, offering new avenues for therapeutic intervention.
Two pioneering companies are poised to explore the genetic frontiers of probiotic bacteria, seeking out strains that can produce sustainable quantities of life-enhancing microbial metabolites.
